HC Wainwright Initiates Coverage on Coya Therapeutics (NASDAQ:COYA)

HC Wainwright began coverage on shares of Coya Therapeutics (NASDAQ:COYA) in a research report report published on Monday, Benzinga reports. The firm issued a buy rating and a $18.00 price target on the stock.

COYA has been the topic of several other reports. Chardan Capital reaffirmed a buy rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, June 5th. Rodman & Renshaw assumed coverage on Coya Therapeutics in a research report on Thursday, June 13th. They set a buy rating and a $18.00 price target on the stock.

Coya Therapeutics Price Performance

Shares of COYA stock opened at $6.28 on Monday. The firm has a market capitalization of $91.80 million, a price-to-earnings ratio of -7.39 and a beta of 0.58. The business has a fifty day moving average of $6.33 and a 200 day moving average of $7.58. Coya Therapeutics has a 1 year low of $3.21 and a 1 year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The business had revenue of $3.43 million during the quarter. As a group, equities research analysts expect that Coya Therapeutics will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently modified their holdings of the business. Greenlight Capital Inc. grew its position in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after acquiring an additional 805,959 shares during the period. AIGH Capital Management LLC boosted its holdings in Coya Therapeutics by 92.6% in the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after buying an additional 496,183 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Coya Therapeutics in the 2nd quarter worth about $101,000. Finally, Gilbert & Cook Inc. acquired a new stake in Coya Therapeutics in the 2nd quarter worth about $61,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.